PLAUR and lung cancer: Urokinase-type plasminogen activator receptor (uPAR), commonly upregulated on senescent cells, has been exploited for uPAR-specific CAR-T cell therapies to selectively eliminate senescent cells in vitro and in vivo, leading to improved outcomes in mouse models of lung cancer and liver fibrosis (213).